The European Commission has approved Wayrilz (rilzabrutinib), a novel oral Bruton’s tyrosine kinase (BTK) inhibitor, for adult patients with immune…
Read More

The European Commission has approved Wayrilz (rilzabrutinib), a novel oral Bruton’s tyrosine kinase (BTK) inhibitor, for adult patients with immune…
Read More